Misplaced Pages

Amulirafusp alfa (IMM0306) is a cancer immunotherapy that targets CD20-positive B-cell malignancies. It is a fusion protein that combines a CD20 monoclonal antibody with the CD47 binding domain of SIRPα, allowing it to simultaneously engage both CD20 and CD47 on cancer cells. Amulirafusp alfa has a dual mechanism of action that enhances both macrophage-mediated phagocytosis and natural killer cell activation.

References

1. Yang J, Song Y, Zhou K, Li Z, Zhang M, Jing H, Wang Z, Yu L, Meng W, Lu Q, Tian W, Shi Y (December 2024). "Safety and efficacy of amulirafusp alfa (IMM0306), a fusion protein of CD20 monoclonal antibody with the CD47 binding domain of SIRPα, in patients with relapsed or refractory B-cell non-Hodgkin lymphoma: a phase 1/2 study". Journal of Hematology & Oncology. 17 (1): 123. doi:10.1186/s13045-024-01646-2. PMC 11657391. PMID 39696680.
2. Yang J, Li Z, Zhang M, Zhou K, Li Y, Yang Y, Wang Z, Yu L, Zhang J, Huang H, Cheng Y (September 2024). "839P Preliminary results from a phase II study of amulirafusp alfa (IMM0306) in patients with relapsed or refractory CD20-positive B-cell non-Hodgkin's lymphoma". Annals of Oncology. 35: S610. doi:10.1016/j.annonc.2024.08.890.

This pharmacology-related article is a stub. You can help Misplaced Pages by expanding it.

• v
• t
• e

• Pharmacology stubs
• Monoclonal antibodies